Vertex Pharmaceuticals Inc
Stock Details
Is it expensive?
Trailing P/E Ratio
26.25
Forward P/E Ratio
20.57
PEG Ratio
0.43
21.45
Price-to-Sales (TTM)
9.18
5.80
76.18
Market Cap
112.12B
106.86B
Is it profitable?
Net Profit Margin (TTM)
35.51%
Gross Profit Margin
86.85%
Diluted EPS (TTM)
16.83
24.20%
12.22B
Is it growing?
7.80%
59.60%
Is it risky?
0.30
10.26
3.02
1.99B
Who owns it?
97.89%
0.20%
1.99%
254.16M
253.02M
Does it pay?
0.00%
0.00%
--
--
How much cash?
7.25B
4.24B
2.78B
28.55
- Price
- 446.83
- Percent Change
- +5.09 (1.15%)
- Previous Close
- 441.74
- Open
- 445.94
- Low
- 443.87
- High
- 453.15
52-Week Range Position (52WRP)
Fairly Priced
Fairly Priced
within its 1-year price range
$446.83
From 52W Low
+23.26%
From 52W High
-12.03%
Today
+1.15%
1Y Change
+0.68%
6M
$455.48
3M
$460.82
1M
$424.36
Today
$446.83
From 52W Low
+23.26%
From 52W High
-12.03%
Today
+1.15%
1Y Change
+0.68%
6M
$455.48
3M
$460.82
1M
$424.36
Today
$446.83
Fairly Priced
within its 1-year price range
$446.83
Multi-Timeframe Analysis (MTA)
Divergence
Timeframes disagree. Short and long-term momentum are pulling in different directions, which historically signals higher uncertainty and potential turning points. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+5.3%
3M
-3.0%
6M
-1.9%
1Y
+0.7%
Rate of Change (ROC)
Decelerating
Price has reversed, now rising vs its usual downtrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Vertex Pharmaceuticals Inc
- Founded
- 1989
- CEO
- Reshma Kewalramani
- Employees
- 6,400
- Fiscal Year End
- Dec 31, 2024
- Address
50 Northern Avenue
Boston
Massachusetts
02210
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.vrtx.com
Indicators
Operating Cash Flow
4.24B
Net Income
4.34B
Backed by Cash
0.98
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Related Heatmaps
NASDAQ 100Index NASDAQ-100 - NDX |
S&P 500Index S&P 500 - SPX |
Indicators
Operating Cash Flow
4.24B
Net Income
4.34B
Backed by Cash
0.98
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
26.25
Forward P/E Ratio
20.57
PEG Ratio
0.43
21.45
Price-to-Sales (TTM)
9.18
5.80
76.18
Market Cap
112.12B
106.86B
Is it profitable?
Net Profit Margin (TTM)
35.51%
Gross Profit Margin
86.85%
Diluted EPS (TTM)
16.83
24.20%
12.22B
Is it growing?
7.80%
59.60%
Is it risky?
0.30
10.26
3.02
1.99B
Who owns it?
97.89%
0.20%
1.99%
254.16M
253.02M
Does it pay?
0.00%
0.00%
--
--
How much cash?
7.25B
4.24B
2.78B
28.55
- Price
- 446.83
- Percent Change
- +5.09 (1.15%)
- Previous Close
- 441.74
- Open
- 445.94
- Low
- 443.87
- High
- 453.15
52-Week Range Position (52WRP)
Fairly Priced
Fairly Priced
within its 1-year price range
$446.83
From 52W Low
+23.26%
From 52W High
-12.03%
Today
+1.15%
1Y Change
+0.68%
6M
$455.48
3M
$460.82
1M
$424.36
Today
$446.83
From 52W Low
+23.26%
From 52W High
-12.03%
Today
+1.15%
1Y Change
+0.68%
6M
$455.48
3M
$460.82
1M
$424.36
Today
$446.83
Fairly Priced
within its 1-year price range
$446.83
Multi-Timeframe Analysis (MTA)
Divergence
Timeframes disagree. Short and long-term momentum are pulling in different directions, which historically signals higher uncertainty and potential turning points. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+5.3%
3M
-3.0%
6M
-1.9%
1Y
+0.7%
Rate of Change (ROC)
Decelerating
Price has reversed, now rising vs its usual downtrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Vertex Pharmaceuticals Inc
- Founded
- 1989
- CEO
- Reshma Kewalramani
- Employees
- 6,400
- Fiscal Year End
- Dec 31, 2024
- Address
50 Northern Avenue
Boston
Massachusetts
02210
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.vrtx.com
Related Heatmaps
NASDAQ 100Index NASDAQ-100 - NDX |
S&P 500Index S&P 500 - SPX |